Open Access

Influence of camel milk on the hepatitis C virus burden of infected patients

  • Authors:
    • Esmail Mohamad El‑Fakharany
    • Nawal Abd El‑Baky
    • Mustafa Hassan Linjawi
    • Abdullah Abdelhafiz Aljaddawi
    • Tahya Hussein Saleem
    • Ahmed Yassine Nassar
    • Ashraf Osman
    • Elrashdy Moustafa Redwan
  • View Affiliations

  • Published online on: February 22, 2017     https://doi.org/10.3892/etm.2017.4159
  • Pages: 1313-1320
  • Copyright: © El‑Fakharany et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatitis C virus (HCV) infection represents a world health problem and no protective vaccine or effective drug currently exists. For economic reasons, many patients use traditional medicines to control the infection. In Egypt, camel milk is one of the traditional medicines widely consumed by patients infected with HCV. The present study aimed to evaluate the efficacy of camel milk in the treatment of patients infected with HCV. Whole camel milk from a local farm was administered to patients for 4 months (250 ml/day/patient). Patient sera were collected prior to and following camel milk drinking, and three markers were set‑up for sera‑evaluation. The three markers indicating the effect of camel milk on HCV infection were: Liver function assays [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)]; a viral load assay; and anti‑HCV antibodies profile and isotyping against synthetic HCV epitopes. Camel milk demonstrated the ability to improve general fatigue, health and liver function (ALT and AST levels); ALT was reduced in ~88% of patients and AST was reduced in all patients subsequent to drinking camel milk for four months. The majority of patients responded positively to camel milk treatment; RNA viral load decreased in 13 out of the 17 patients (76.47%) and one patient exhibited undetected viremia following camel milk treatment. The anti‑HCV antibodies profile and isotyping were significantly decreased (P<0.05) in immunoglobulin (Ig)G1 following treatment in 70‑76% of patients. However, the treatment was ineffective in 23.53% of patients who experienced no reduction in RNA viral load following treatment with camel milk. In conclusion, whole camel milk treatment demonstrated efficacy in vivo; the viral load in the majority of patient sera was reduced and the IgG isotype profile was converted to Th1 immunity.

References

1 

Williams R: Global challenges in liver disease. Hepatology. 44:521–526. 2006. View Article : Google Scholar : PubMed/NCBI

2 

Shepard CW, Finelli L and Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 5:558–567. 2005. View Article : Google Scholar : PubMed/NCBI

3 

Deuffic-Burban S, Poynard T, Sulkowski MS and Wong JB: Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat. 14:107–115. 2007. View Article : Google Scholar : PubMed/NCBI

4 

Ly KN, Hughes EM, Jiles RB and Holmberg SD: Rising mortality associated with hepatitis C virus in the united states, 2003–2013. Clin Infect Dis. 62:1287–1288. 2016. View Article : Google Scholar : PubMed/NCBI

5 

Chung RT: Acute hepatitis C virus infection. Clin Infect Dis. 41 Suppl 1:S14–S17. 2005. View Article : Google Scholar : PubMed/NCBI

6 

Ghany MG, Strader DB, Thomas DL and Seeff LB: American Association for the Study of Liver Diseases. Diagnosis, management and treatment of hepatitis C An update. Hepatology. 49:1335–1374. 2009. View Article : Google Scholar : PubMed/NCBI

7 

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M and Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 358:958–965. 2001. View Article : Google Scholar : PubMed/NCBI

8 

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347:975–982. 2002. View Article : Google Scholar : PubMed/NCBI

9 

Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C and Albrecht J: Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 352:1426–1432. 1998. View Article : Google Scholar : PubMed/NCBI

10 

Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, Nishioji K, Murakami Y and Kashima K: Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in advanced stage: A retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol. 30:653–659. 1999. View Article : Google Scholar : PubMed/NCBI

11 

Booth JC, O'Grady J and Neukerger J: Thr Royal College of Physicians of London and the British Society of Gastroenterology: Clinical guidelines on the management of hepatitis C. Gut. 49 Suppl 1:I1–I21. 2001. View Article : Google Scholar : PubMed/NCBI

12 

Ray SC, Arthur RR, Carella A, Bukh J and Thomas DL: Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis. 182:698–707. 2000. View Article : Google Scholar : PubMed/NCBI

13 

Shiha G and Salem S: Interferon alone or in combination with ribavirin for the treatment of chronic hepatitis C genotype IV. J Hepatol. 36:1292002. View Article : Google Scholar

14 

El Makhzangy H, Esmat G, Said M, Elraziky ME, Shouman S, Refai R, Rekacewicz C, Gad RR, Vignier N, Abdel-Hamid M, et al: Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol. 81:1576–1583. 2009. View Article : Google Scholar : PubMed/NCBI

15 

Esmat G and Fattah S Abdel: Evaluation of a novel pegylated interferon alpha-2a (Reiferon Retard®) in Egyptian patients with chronic hepatitis C-genotype 4. Digest Liver Dis. 3:17–19. 2009.

16 

Yagil R and van Creveld C: Medicinal use of camel milk. Fact or Fancy?Proceedings of the 2nd International Camelid Conference on Agro-economics of Camelids. Almaty; Kazahstan: 2000

17 

Yagil R and Combs SB: The Desert Camel: Comparative Physiological AdaptationComparative Animal Nutrition. 5. Karger, Basel: 1985

18 

Hanna J Over the hump. Jack Hanna's Animal Adventures. TV series (USA) 2001 season. #2190. simplewww.animaladventures.com

19 

Merin U, Bernstein SD, Bloch-Damti N, Yagil R, van Creveld C and Lindner P: A comparative study of milk proteins in camel (Camelus dromedarius) and bovine colostrum. Livestock Product Sci. 67:297–301. 2001. View Article : Google Scholar

20 

Beg OU, von-Bahr-Lindstström H, Zaidi ZH and Jörnvall H: Characterisation of camel milk protein rich proline identifies a new beta casein fragment. Regul Pept. 15:55–61. 1986. View Article : Google Scholar : PubMed/NCBI

21 

Evans EW: Uses of milk proteins in formulated foodsDevelopments in Food Proteins. Hudson BJF: Applied Science; London: 1982

22 

EL-Fakharany EM, Serour EA, Abdelrahman AM, Haroun BM and Redwan el-RM: Purification and characterization of camel (Camelus dromedarius) milk amylase. Prep Biochem Biotechnol. 39:105–123. 2009. View Article : Google Scholar : PubMed/NCBI

23 

Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa E Bajyana, Bendahman N and Hamers R: Naturally occurring antibodies devoid of light chains. Nature. 363:446–448. 1993. View Article : Google Scholar : PubMed/NCBI

24 

Håkansson A, Zhivotovsky B, Orrenius S, Sabharwal H and Svanborg C: Apoptosis induced by a human milk protein. Proc Natl Acad Sci. 92:8064–8068. 1995. View Article : Google Scholar : PubMed/NCBI

25 

Harmsen MC, Swart PJ, de Bethune MP, Pauwels R, De Clercq E, The TH and Meijer DK: Antiviral effects of plasma and milk proteins: Lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis. 172:380–388. 1995. View Article : Google Scholar : PubMed/NCBI

26 

Redwan el-RM and Tabll A: Camel lactoferrin markedly inhibits hepatitis C virus genotype 4 infection of human peripheral blood leukocytes. J Immunoassay Immunochem. 28:267–277. 2007. View Article : Google Scholar : PubMed/NCBI

27 

El-Fakharany EM, Tabll A, El-Wahab AA, Haroun BM and Redwan EM: Potential activity of camel milk-amylase and lactoferrin against hepatitis C virus infectivity in HepG2 and lymphocytes. Hepatitis Monthly. 8:101–109. 2008.

28 

Valenti P and Antonini G: Lactoferrin: An important host defense against microbial and viral attack. Cell Mol Life Sci. 62:2576–2587. 2005. View Article : Google Scholar : PubMed/NCBI

29 

El-Fakharany EM, Haroun BM, Ng TB and Redwan EM: Oyster mushroom laccase inhibits hepatitis C virus entry into peripheral blood cells and hepatoma cells. Protein Pept Lett. 17:1031–1039. 2010. View Article : Google Scholar : PubMed/NCBI

30 

Rao MB, Gupta RC and Dastur NN: Camels' milk and milk products. Ind J Dairy Sci. 23:71–78. 1970.

31 

Kaskous S: Importance of camel milk for human health. Emir J Food Agric. 28:158–163. 2016.

32 

Almahdy O, EL-Fakharany EM, EL-Dabaa E, Ng TB and Redwan EM: Examination of the activity of camel milk casein against hepatitis C virus (genotype-4a) and its apoptotic potential in hepatoma and hela cell lines. Hepat Mon. 11:724–730. 2011. View Article : Google Scholar : PubMed/NCBI

33 

Liao Y, El-Fakharany E, Lönnerdal B and Redwan EM: Inhibitory effects of native and recombinant full-length camel lactoferrin and its N and C lobes on hepatitis C virus infection of Huh7.5 cells. J Med Microbiol. 61:375–383. 2012. View Article : Google Scholar : PubMed/NCBI

34 

EL-Fakharany EM, Abedelbaky N, Haroun BM, Sánchez L, Redwan NA and Redwan EM: Anti-infectivity of camel polyclonal antibodies against hepatitis C virus in Huh7.5 hepatoma. Virol J. 9:2012012. View Article : Google Scholar : PubMed/NCBI

35 

EL-Fakharany EM, Haroun BM, Redwan NA, Sánchez L and Redwan EM: Potential activity of camel milk proteins on the cellular infectivity of hepatitis C virus. Virol J. 9:2012012. View Article : Google Scholar : PubMed/NCBI

36 

El-Fakharany EM, Sánchez L, Al-Mehdar HA and Redwan EM: Effectiveness of human, camel, bovine and sheep lactoferrin on the hepatitis C virus cellular infectivity: Comparison study. Virol J. 10:1992013. View Article : Google Scholar : PubMed/NCBI

37 

Redwan EM, Uversky VN, El-Fakharany EM and Al-Mehdar H: Potential lactoferrin activity against pathogenic viruses. C R Biol. 337:581–595. 2014. View Article : Google Scholar : PubMed/NCBI

38 

Albar AH, Almehdar HA, Uversky VN and Redwan EM: Structural heterogeneity and multifunctionality of lactoferrin. Curr Protein Pept Sci. 15:778–797. 2014. View Article : Google Scholar : PubMed/NCBI

39 

Redwan EM, El-Fakharany EM, Uversky VN and Linjawi MH: Screening the anti infectivity potentials of native N- and C-lobes derived from the camel lactoferrin against hepatitis C virus. BMC Complement Altern Med. 14:2192014. View Article : Google Scholar : PubMed/NCBI

40 

Almehdar HA, El-Fakharany EM, Uversky VN and Redwan EM: Disorder in milk proteins: Structure, functional disorder, and biocidal potentials of lactoperoxidase. Curr Protein Pept Sci. 16:352–365. 2015. View Article : Google Scholar : PubMed/NCBI

41 

Redwan EM, Almehdar HA, EL-Fakharany EM, Baig AWK and Uversky VN: Potential antiviral activities of camel, bovine, and human lactoperoxidases against hepatitis C virus genotype 4. RSC Adv. 5:60441–60452. 2015. View Article : Google Scholar

42 

Redwan EM, El-Baky NA, Al-Hejin AM, Baeshen MN, Almehdar HA, Elsaway A, Gomaa AB, Al-Masaudi SB, Al-Fassi FA, Abu Zeid IE and Uversky VN: Significant antibacterial activity and synergistic effects of camel lactoferrin with antibiotics against methicillin-resistant Staphylococcus aureus (MRSA). Res Microbiol. 167:480–491. 2016. View Article : Google Scholar : PubMed/NCBI

43 

Dogar MZ Hassan, Nazir T, Akram H, Nasir-ud-Din A and Farooq M: Molecular study of human HCV RNA by real time-polymerase chain reaction, viral kit and RoboGene quantification. Cell Mol Biol. 61:22015.PubMed/NCBI

44 

Redwan el-RM, Fahmy A, El Hanafy A, Abd EL-Baky N and Sallam SM: Ovine anti-rabies antibody production and evaluation. Comp Immunol Microbiol Infect Dis. 32:9–19. 2009. View Article : Google Scholar : PubMed/NCBI

45 

EL-Baky NA, Omar SH, EL-Badry H and Redwan el-RM: Efficacy comparison of gel-based, membrane and glass array techniques to detect human antibodies isotypes among the Egyptian HCV-patients. Hum Antibodies. 17:63–71. 2008.PubMed/NCBI

46 

Thompson JD, Higgins DG and Gibson TJ: CLUSTAL W Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673–4680. 1994. View Article : Google Scholar : PubMed/NCBI

47 

Kuiken C, Yusim K, Boykin L and Richardson R: The Los Alamos hepatitis C sequence database. Bioinformatics. 21:379–384. 2005. View Article : Google Scholar : PubMed/NCBI

48 

Fields GB and Noble RL: Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res. 35:161–214. 1990. View Article : Google Scholar : PubMed/NCBI

49 

Boysen RI and Hearn MT: Purification of peptides from solid-phase peptide synthesis with RP-HPLC. CSH Protoc. 2006:pdb.prot45482006.PubMed/NCBI

50 

Conover WJ: Practical nonparametric statistic. 2nd edition. John Wiley and Sons; New York: 1971

51 

el-Zayadi A, Simmonds P, Dabbous H, Prescott L, Selim O and Ahdy A: Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4. J Viral Hepat. 3:261–264. 1996. View Article : Google Scholar : PubMed/NCBI

52 

Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, Saleh WA, Ismail A, Aziz AA and Madwar MA: Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response. Gut. 54:858–866. 2005. View Article : Google Scholar : PubMed/NCBI

53 

El-Zanaty F and Way A: Egypt Demographic and Health Survey 2008. Egyptian Ministry of Health. El-Zanaty and Associates and Macro International. 4312009.

54 

Zekri AK, Ashour MS, Hassan A, El-Din H Alam, El-Shehaby AM and Abu-Shady MA: Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression. World J Gastroenterol. 11:6624–6630. 2005. View Article : Google Scholar : PubMed/NCBI

55 

El-Baky NA, Omar SH and Redwan EM: The anti-cancer activity of human consensus interferon-alpha synthesized in cell-free system. Protein Expr Purif. 80:61–67. 2011. View Article : Google Scholar : PubMed/NCBI

56 

Mohammed Y, El-Baky NA and Redwan EM: Expression, purification, and characterization of recombinant human consensus interferon-alpha in Escherichia coli under λp(L) promoter. Prep Biochem Biotechnol. 42:426–447. 2012. View Article : Google Scholar : PubMed/NCBI

57 

Elattar G, Saleh Z, EL-Shebini S, Farrag A, Zoheiry M, Hassanein A, EL-Ghannam M, Shendy S, EL-Dabaa E and Zahran N: The use of whey protein concentrate in management of chronic hepatitis C virus-a pilot study. Arch Med Sci. 5:748–755. 2010. View Article : Google Scholar

58 

Abbas S, Imran R, Nazir A, Qamar MF and Sarfraz L: Effect of camel milk supplementation on blood parameters and liver function of hepatitis patients. Am J Ethnomedicine. 1:129–146. 2014.

59 

Mohamed WA, Schaalan MF and El-Abhar HS: Camel milk: Potential utility as an adjunctive therapy to Peg-IFN/RBV in HCV-4 infected patients in Egypt. Nutr Cancer. 67:1305–1313. 2015. View Article : Google Scholar : PubMed/NCBI

60 

Park GJH, Lin BP, Ngu MC, Jones DB and Katelaris PH: Aspartate aminotransferases: Alanine aminotransferases ratio in chronic hepatitis C infection: Is it a predictor of cirrhosis? J Gastroenterol Hepatol. 15:386–390. 2000. View Article : Google Scholar : PubMed/NCBI

61 

Rosalki SB and Mcintyre N: Biochemical investigations in the management of liver diseaseOxford textbook of clinical hepatology. 2nd edition. New York: Oxford university press; pp. 503–521. 1999

62 

Thapa BR and Walia A: Liver function tests and their interpretation. Indian J Pediatr. 74:663–671. 2007. View Article : Google Scholar : PubMed/NCBI

63 

Roitt V, Brostoff J and Male D: Immunology. 6th edition. Goldsby, Kindt, Osborne, Kuby. Freeman & Company; pp. 8.4–8.5. 2006

64 

Saltanat H, Li H, Xu Y, Wang J, Liu F and Geng XH: The influences of camel milk on the immune response of chronic hepatitis B patients. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 25:431–433. 2009.(In Chinese). PubMed/NCBI

65 

Gigi E, Raptopoulou-Gigi M, Kalogeridis A, Masiou S, Orphanou E, Vrettou E, Lalla TH, Sinakos E and Tsapas V: Cytokine mRNA expression in hepatitis C virus infection: TH-1 predominance in patients with chronic hepatitis C and TH1-TH2 cytokine profile in subjects with self-limited disease. J Viral Hepat. 15:145–154. 2008.PubMed/NCBI

66 

Breitling L: Insulin and anti-diabetes activity of camel milk. J Camel Practice Research. 9:43–45. 2002.

67 

Martin F, Volpari C, Steinkuhler C, Dimas N, Brunetti M, Biasiol G, Altamura S, Cortese R, De Francesco R and Sollazzo M: Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 protease. Protein Eng. 10:607–614. 1997. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2017
Volume 13 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
El‑Fakharany, E.M., El‑Baky, N.A., Linjawi, M.H., Aljaddawi, A.A., Saleem, T.H., Nassar, A.Y. ... Redwan, E.M. (2017). Influence of camel milk on the hepatitis C virus burden of infected patients. Experimental and Therapeutic Medicine, 13, 1313-1320. https://doi.org/10.3892/etm.2017.4159
MLA
El‑Fakharany, E. M., El‑Baky, N. A., Linjawi, M. H., Aljaddawi, A. A., Saleem, T. H., Nassar, A. Y., Osman, A., Redwan, E. M."Influence of camel milk on the hepatitis C virus burden of infected patients". Experimental and Therapeutic Medicine 13.4 (2017): 1313-1320.
Chicago
El‑Fakharany, E. M., El‑Baky, N. A., Linjawi, M. H., Aljaddawi, A. A., Saleem, T. H., Nassar, A. Y., Osman, A., Redwan, E. M."Influence of camel milk on the hepatitis C virus burden of infected patients". Experimental and Therapeutic Medicine 13, no. 4 (2017): 1313-1320. https://doi.org/10.3892/etm.2017.4159